These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 26315816)

  • 1. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.
    Nelson AG; Zhang X; Ganapathi U; Szekely Z; Flexner CW; Owen A; Sinko PJ
    J Control Release; 2015 Dec; 219():669-680. PubMed ID: 26315816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges.
    Agrahari V; Anderson SM; Peet MM; Wong AP; Singh ON; Doncel GF; Clark MR
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1365-1380. PubMed ID: 36252277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review.
    Elliott T; Sanders EJ; Doherty M; Ndung'u T; Cohen M; Patel P; Cairns G; Rutstein SE; Ananworanich J; Brown C; Fidler S
    J Int AIDS Soc; 2019 Dec; 22(12):e25419. PubMed ID: 31850686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review.
    Mayer KH; Agwu A; Malebranche D
    Adv Ther; 2020 May; 37(5):1778-1811. PubMed ID: 32232664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling HIV Pre-Exposure Prophylaxis.
    Straubinger T; Kay K; Bies R
    Front Pharmacol; 2019; 10():1514. PubMed ID: 32082142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead.
    Sosnik A; Chiappetta DA; Carcaboso AM
    J Control Release; 2009 Aug; 138(1):2-15. PubMed ID: 19445981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches for CNS delivery of drugs - nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment.
    Gupta S; Kesarla R; Omri A
    Expert Opin Drug Deliv; 2019 Mar; 16(3):287-300. PubMed ID: 30779602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV/AIDS in Indonesia: current treatment landscape, future therapeutic horizons, and herbal approaches.
    Jocelyn ; Nasution FM; Nasution NA; Asshiddiqi MH; Kimura NH; Siburian MHT; Rusdi ZYN; Munthe AR; Chairenza I; Ginting Munthe MCFB; Sianipar P; Gultom SP; Simamora D; Uswanas IR; Salim E; Khairunnisa K; Syahputra RA
    Front Public Health; 2024; 12():1298297. PubMed ID: 38420030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
    McGowan I
    Am J Reprod Immunol; 2014 Jun; 71(6):624-30. PubMed ID: 24635047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV prevention: better choice for better coverage.
    Bekker LG; Pike C; Hillier SL
    J Int AIDS Soc; 2022 Jan; 25(1):e25872. PubMed ID: 35030296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting slow effective release antiretroviral therapy.
    Edagwa B; McMillan J; Sillman B; Gendelman HE
    Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From modeling to morals: imagining the future of HIV PREP in Lesotho.
    Kenworthy NJ; Bulled N
    Dev World Bioeth; 2013 Aug; 13(2):70-8. PubMed ID: 23800326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Polymer Blending on the Performance of a Subcutaneous Biodegradable Implant for HIV Pre-Exposure Prophylaxis (PrEP).
    Li L; Areson C; van der Straten A; Johnson LM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207212
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.